Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer

Anti-Cancer Drugs

Volumn 21, Issue 8, 2010, Pages 749-758

  Oostendorp, Linda J M ^a   Stalmeier, Peep F ^a   Pasker De Jong, Pieternel C ^a   Van Der Graaf, Winette T ^a   Ottevanger, Petronella B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

chemotherapy; colorectal cancer; irinotecan; palliative; second line

Indexed keywords

FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN;

ADVANCED CANCER; ALOPECIA; ANOREXIA; ASTHENIA; CANCER CONTROL; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; FATIGUE; HUMAN; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; STOMATITIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 77955229256     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32833c57cf     Document Type: Review

References (49)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. Scheithauer W, KornekGV, Brugger S, Ullrich-Pur H,ValencakJ, Raderer M, et al. Randomized phase II study of irinotecan plus mitomycin C versus oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/ leucovorin-pretreated colorectal cancer. Cancer Invest 2002; 20:60-68. (Pubitemid 34151060)
3. Cunningham D, Maroun J, Vanhoefer U, Cutsem van E. Optimizing the use of irinotecan in colorectal cancer. Oncologist 2001; 6 (Suppl 4):1 7-23.
4. Cutsem van E, Oliveira J. Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl 4):61-63.
5. Cutsem van E, Dirix L, Van Laethem JL, Belle van S, Borner M, Gonzalez Baron M, et al. Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study. Br J Cancer 2005; 92:1055-1062.
6. Fuchs C, Mitchell EP, Hoff PM. Irinotecan in the treatment of colorectal cancer. Cancer Treat Rev 2006; 32:491-503.
7. Mitry E, Lievre A, Bachet J, Rougier P. Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatment. Int J Colorectal Dis 2009; 24:605-612.
8. Roque i Figuls M, Sola I, Martin-Richard M, Lopez J, Bonfill Cosp X. Second- line chemotherapy in advanced and metastatic CRC. Cochrane Database Syst Rev 2009, Issue 2. Art. No.: CD006875. DOI: 10.1002/ 14651858.CD006875.pub2.
9. Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 2001; 19:1501-1518. (Pubitemid 32202559)
10. Zia MI, Siu LL, Pond GR, Chen EX. Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. J Clin Oncol 2005; 23:6982-6991.
11. Lidstone V, Butters E, Seed PT, Sinnott C, Beynon T, Richards M. Symptoms and concerns amongst cancer outpatients: identifying the need for specialist palliative care. Palliat Med 2003; 17:588-595.
12. Stromgren AS, Sjogren P, Goldschmidt D, Petersen MA, Pedersen L, Groenvold M. Symptom priority and course of symptomatology in specialized palliative care. J Pain Symptom Manage 2006; 31:199-206.
13. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62:1006-1012.
14. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993; 11:909-913.
15. Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA III, Nelson J, Hilsenbeck SG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996; 14:1128-1135.
16. Pitot HC, Wender DB, O'Connell MJ, Schroeder G, Goldberg RM, Rubin J, et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997; 15:2910-2919.
17. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15:251-260.
18. Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE, et al. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 1999; 85:786-795.
19. Van Cutsem E, Cunningham D, Bokkel Huinink ten WW, Punt CJ, Alexopoulos CG, Dirix L, et al. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur J Cancer 1999; 35:54-59.
20. Ratanatharathorn V, Sirachainan E, Jirajarus M, Sirilerttrakul S. Clinical activity and benefit of irinotecan (CPT-11) in patients with metastatic colorectal carcinoma pre-treated with fluorouracil-based chemotherapy. J Med Assoc Thai 2000; 83:1187-1195.
21. Ulrich-Pur H, Kornek GV, Fiebiger W, Gedlicka C, Raderer M, Lenauer A, et al. Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy. Ann Oncol 2001; 12:1269-1272.
22. Michael M, Hedley D, Oza A, Feld R, Pintilie M, Goel R, et al. The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial. Clin Colorectal Cancer 2002; 2:93-101.
23. See HT, Koo WH, Ang P, Au E, Ang PT. Efficacy and tolerability of irinotecan in patients with advanced colorectal cancer in Singapore. Ann Acad Med Singapore 2002; 31:651-655.
24. Tsavaris NB, Polyzos A, Gennatas K, Kosmas Ch, Vadiaka M, Dimitrakopoulos A, et al. Irinotecan (CPT-11) in patients with advanced colon carcinoma relapsing after 5-fluorouracil-leucovorin combination. Chemotherapy 2002; 48:94-99.
25. Anton A, Aranda E, Carrato A, Marcuello E, Massutti B, Cervantes A, et al. Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. Methods Find Exp Clin Pharmacol 2003; 25:639-643.
26. Cassinello J, Lopez-Alvarez P, Martinez-Guisado A, Valladares M, Huidobro G, Lopez R, et al. Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer. Med Oncol 2003; 20:37-43.
27. Cerea G, Vaghi M, Ardizzoia A, Villa S, Bucovec R, Mengo S, et al. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations. Anticancer Res 2003; 23:1951-1954.
28. Karaoglu A, Yalcin S, Tekuzman G, Kars A, Celik I, Guler N, et al. Weekly irinotecan in patients with metastatic colorectal cancer failing 5-fluorouracil-based chemotherapy: efficacy and prognostic factors. Tumori 2003; 89:141-145.
29. Mendez M, Salut A, Garcia-Giran C, Navalon M, Diz P, Garcia Lopez MJ, et al. A multicenter phase II study of irinotecan in patients with advanced colorectal cancer previously treated with 5-fluorouracil. Clin Colorectal Cancer 2003; 3:174-179.
30. Tsavaris N, Ziras N, Kosmas C, Giannakakis T, Gouveris P, Vadiaka M, et al. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination: a randomized study. Cancer Chemother Pharmacol 2003; 52:514-519.
31. Vieitez JM, Carrasco J, Esteban E, Fra J, Alvarez E, Muniz I, et al. Irinotecan in the treatment of advanced colorectal cancer in patients pretreated with fluorouracil-based chemotherapy: a study to determine recommendable therapeutic dosage. Am J Clin Oncol 2003; 26:107-111.
32. Benavides M, Garcia-Alfonso P, Cobo M, Munoz-Martin A, Gil-Calle S, Carabantes F, et al. Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer. Med Oncol 2004; 21:255-262.
33. Hartmann JT, Oechsle K, Jager E, Reis HE, Haag C, Niederle N, et al. Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil. Anticancer Drugs 2004; 15:473-477.
34. Saigi E, Salut A, Campos JM, Losa F, Manzano H, Batiste-Alentorn E, et al. Phase II study of irinotecan (CPT-11) administered every 2 weeks as treatment for patients with colorectal cancer resistant to previous treatment with 5-fluorouracil-based therapies: comparison of two different dose schedules (250 and 200mg/m2) according to toxicity prognostic factors. Anticancer Drugs 2004; 15:835-841.
35. Schoemaker NE, Kuppens IE, Moiseyenko V, Glimelius B, Kjaer M, Starkhammer H, et al. A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer. Br J Cancer 2004; 91:1434-1441.
36. Garcia-Giron C, Garcia Palomo A, Alonso Lopez C, Leon Carbonero A, Mendez Urena M, Adroover Cebrian E, et al. Phase II trial of fortnightly irinotecan (CPT-11) in the treatment of colorectal cancer patients resistant to previous fluoropyrimidine-based chemotherapy. Clin Transl Oncol 2005; 7:244-249.
37. Graeven U, Arnold D, Reinacher-Schick A, Heuer T, Nusch A, Porschen R, et al. A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma. Onkologie 2007; 30:169-1 74.
38. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352:1413-1418.
39. Rougier P, Cutsem van E, Bajetta E, Niederle N, Possinger K, Labianca R, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352:1407-1412.
40. Aravantinos G, Skarlos DV, Kosmidis P, Georgoulias V, Sgouros I, Bafaloukos D, et al. Irinotecan (CPT-11) in patients with advanced colorectal cancer previously treated with 5-fluorouracil-based chemotherapy. Crit Rev Oncol Hematol 1999; 32:209-219.
41. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003; 21:807-814.
42. Chau I, Norman AR, Cunningham D, Waters JS, Topham C, Middleton G, et al. Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Br J Cancer; 2004;91: 1453-1458
43. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85:365-376.
44. Elting LS, Cooksley C, Bekele BN, Frumovitz M, Avritscher EB, Sun C, et al. Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer 2006; 106:2452-2458.
45. Bokkel Huinink ten WW, Groeningen van CJ, Voest EE, Peters WG, Keizer HJ, Witte de JH. Compassionate use programme of irinotecan in colorectal cancer patients in The Netherlands. Neth J Med 2003; 61:249-256.
46. Tam VC, Rask S, Koru-Sengul T, Dhesy-Thind S. Generalizability of toxicity data from oncology clinical trials to clinical practice: toxicity of irinotecan-based regimens in patients with metastatic colorectal cancer. Curr Oncol 2009; 16:13-20.
47. Yildiz R, Buyukberber S, Uner A, Yamac D, Coskun U, Kaya AO, et al. Bevacizumab plus irinotecan-based therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimens. Cancer Invest 2010; 28:33-37.
48. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:2311-2319.
49. EGAPP Working Group. Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genet Med 2009; 11:15-20.